Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Tirumotecan in Advanced Thymic Epithelial Tumors
NCT07343453Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 2 trial of sacituzumab tirumotecan in thymic epithelial tumor (TET), sponsored by Sun Yat-sen University. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
thymic epithelial tumor (TET)
Beyond the preview
Go deeper on NCT07343453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07343453.